Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXT-1003 in Relapsed/Refractory Non-Hodgkin Lymphomas
NCT05965505Phase 1Terminated
- Sponsor
- Axter Therapeutics
- Start
- Aug 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AXT-1003 in non-Hodgkin lymphoma (NHL) and peripheral T-cell lymphoma (PTCL), sponsored by Axter Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events and 1 more. Started Aug 2023; status: terminated.
02
Drugs
AXT-1003
03
Conditions
non-Hodgkin lymphoma (NHL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05965505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05965505.